NCT04048278
Lidocaine Infusion in Pancreatic Cancer
Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatmentUniversity of Illinois at ChicagoInvestigator-initiated
~46 participants
Updated 2026-06-15 on ClinicalTrials.gov
What's tested:Lidocaine HydrochlorideSaline Solution for Injection
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Specimen outcome measure.
Measured over Outcomes will be evaluated perioperatively
+3 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesIllinois1
Study leadership
- Gina E. Votta-Velis, MD PhD · PRINCIPAL_INVESTIGATOR · Associate Professor
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Specimen outcome measure.Outcomes will be evaluated perioperatively
Src Tyrosine Kinase Enzymatic activity in CTCs. Fluorescence intensity will be used to measure Src phosphorylation in circulating tumor cells.
- Specimen outcome measure.Outcomes will be evaluated perioperatively
Cytokine Levels in Serum (pg/ml)
- Specimen outcome measure.Outcomes will be evaluated perioperatively
Chemokine levels in serum (pg/ml)
- Upregulation or Downregulation of Gene Expression.Outcomes will be evaluated perioperatively
Upregulation or downregulation of gene expression will be measured with the Real Time (RT) square Profiler Polimerase Chain Reaction (PCR )Array Analysis, and Real Time PCR